ImmunityBio (NASDAQ:IBRX) Trading Up 2.2% – What’s Next?

ImmunityBio, Inc. (NASDAQ:IBRX)’s share price was up 2.2% during mid-day trading on Thursday . The stock traded as high as $7.35 and last traded at $7.30. Approximately 14,023,419 shares traded hands during mid-day trading, a decline of 63% from the average daily volume of 38,415,582 shares. The stock had previously closed at $7.14.

ImmunityBio News Summary

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Company raised ~$100M for global expansion, a near‑term liquidity boost that can support operations and development. ImmunityBio (IBRX) Rallies 15% as Firm Raises $100M For Global Expansion
• Positive Sentiment: Company reported its strongest quarter ever per media coverage, which investors may view as operational momentum despite the controversy. IBRX stock notches strongest quarter ever
• Neutral Sentiment: Multiple law firms are issuing investor alerts and invitations to join or lead class actions — procedural notices that increase public attention and could accelerate filings but do not by themselves change the company’s legal exposure. (Examples: Robbins Geller, Kessler Topaz, Faruqi, Pomerantz, Rosen, Levi & Korsinsky.) Robbins Geller investor notice
• Negative Sentiment: FDA issued a warning letter finding some promotional statements about Anktiva misleading; that regulatory finding triggered a major sell‑off (reported ~21% decline and ~$2B market‑cap loss) and is the core allegation in ensuing securities lawsuits. That materially raises regulatory and litigation risk. Hagens Berman on FDA warning and share plunge
• Negative Sentiment: Several securities‑fraud class actions have been filed (and many firms are soliciting lead‑plaintiff applicants) alleging material misstatements/omissions about Anktiva between Jan 19 and Mar 24, 2026; potential damages and legal costs pose downside risk and could distract management. Kessler Topaz class action announcement

Analyst Ratings Changes

A number of brokerages recently weighed in on IBRX. Piper Sandler reaffirmed an “overweight” rating and set a $12.00 price target (up from $7.00) on shares of ImmunityBio in a research report on Wednesday, March 4th. Weiss Ratings reissued a “sell (e+)” rating on shares of ImmunityBio in a research report on Monday, December 29th. D. Boral Capital restated a “buy” rating and set a $23.00 price objective on shares of ImmunityBio in a research note on Monday, March 23rd. HC Wainwright increased their target price on ImmunityBio from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, February 23rd. Finally, Jefferies Financial Group raised their target price on ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a report on Friday, December 12th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, ImmunityBio has an average rating of “Moderate Buy” and an average target price of $14.40.

ImmunityBio Stock Up 2.2%

The firm’s 50 day moving average price is $7.73 and its two-hundred day moving average price is $4.33. The firm has a market capitalization of $7.51 billion, a PE ratio of -19.21 and a beta of 0.13.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings results on Monday, February 23rd. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.02. The firm had revenue of $38.29 million for the quarter. On average, sell-side analysts anticipate that ImmunityBio, Inc. will post -0.92 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Christobel Selecky sold 50,000 shares of the stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $5.00, for a total value of $250,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Barry J. Simon sold 165,000 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $10.25, for a total value of $1,691,250.00. Following the sale, the director owned 2,925,821 shares of the company’s stock, valued at approximately $29,989,665.25. This trade represents a 5.34% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 501,967 shares of company stock worth $4,466,412. Insiders own 69.48% of the company’s stock.

Institutional Trading of ImmunityBio

A number of hedge funds have recently made changes to their positions in the stock. Slow Capital Inc. acquired a new stake in ImmunityBio in the third quarter valued at $25,000. Truist Financial Corp acquired a new position in ImmunityBio during the 3rd quarter worth $27,000. Swiss Life Asset Management Ltd bought a new stake in shares of ImmunityBio in the 3rd quarter worth about $27,000. WealthPlan Investment Management LLC bought a new stake in shares of ImmunityBio in the 4th quarter worth about $27,000. Finally, Diversify Advisory Services LLC acquired a new stake in shares of ImmunityBio in the 2nd quarter valued at about $27,000. Institutional investors and hedge funds own 8.58% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.